142 related articles for article (PubMed ID: 19906049)
1. Cardiovascular effects of azelnidipine in comparison with those of amlodipine assessed in the halothane-anaesthetized dog.
Ishizaka T; Takahara A; Iwasaki H; Mitsumori Y; Kise H; Nakamura Y; Sugiyama A
Basic Clin Pharmacol Toxicol; 2010 Feb; 106(2):135-43. PubMed ID: 19906049
[TBL] [Abstract][Full Text] [Related]
2. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
Fujisawa M; Yorikane R; Chiba S; Koike H
J Cardiovasc Pharmacol; 2009 Apr; 53(4):325-32. PubMed ID: 19295444
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
Fujisawa M; Yorikane R; Matsuoka Y; Koike H; Ueno K
J Cardiovasc Pharmacol; 2013 Jan; 61(1):63-9. PubMed ID: 23288106
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
Shokoji T; Fujisawa Y; Kiyomoto H; Rahman M; Sun GP; Fan YY; Kimura S; Kohno M; Abe Y; Nishiyama A
Hypertens Res; 2005 Dec; 28(12):1017-23. PubMed ID: 16671342
[TBL] [Abstract][Full Text] [Related]
5. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
Nakamoto M; Ohya Y; Sakima A; Yamazato M; Takishita S
Hypertens Res; 2007 Apr; 30(4):359-66. PubMed ID: 17541215
[TBL] [Abstract][Full Text] [Related]
6. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K
J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.
Yamagishi T
Hypertens Res; 2006 Oct; 29(10):767-73. PubMed ID: 17283863
[TBL] [Abstract][Full Text] [Related]
8. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Konno S; Hirooka Y; Araki S; Koga Y; Kishi T; Sunagawa K
J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
[TBL] [Abstract][Full Text] [Related]
9. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Nagasu H; Satoh M; Fujimoto S; Tomita N; Sasaki T; Kashihara N
Hypertens Res; 2012 Mar; 35(3):348-55. PubMed ID: 22072106
[TBL] [Abstract][Full Text] [Related]
10. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
[TBL] [Abstract][Full Text] [Related]
11. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
Lukic-Panin V; Kamiya T; Zhang H; Hayashi T; Tsuchiya A; Sehara Y; Deguchi K; Yamashita T; Abe K
Brain Res; 2007 Oct; 1176():143-50. PubMed ID: 17904110
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
Yamamoto E; Lai ZF; Yamashita T; Tanaka T; Kataoka K; Tokutomi Y; Ito T; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2006 Oct; 24(10):2057-69. PubMed ID: 16957567
[TBL] [Abstract][Full Text] [Related]
13. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.
Nada T; Nomura M; Koshiba K; Kawano T; Mikawa J; Ito S
Arzneimittelforschung; 2007; 57(11):698-704. PubMed ID: 18193691
[TBL] [Abstract][Full Text] [Related]
14. Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.
Yamada J; Tomiyama H; Matsumoto C; Yoshida M; Shiina K; Yamashina A
J Cardiol; 2008 Apr; 51(2):114-20. PubMed ID: 18522784
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].
Sada T; Saito H
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):539-47. PubMed ID: 14639008
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of azelnidipine and amlodipine on myocardial function and mortality after ischemia/reperfusion in dogs.
Kano S; Ichihara K; Komatsu K; Satoh K
J Pharmacol Sci; 2011; 116(2):181-7. PubMed ID: 21597238
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M
J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.
Ma J; Kishida S; Wang GQ; Meguro K; Imuta H; Oonuma H; Iida H; Jo T; Takano H; Morita T; Nagai R; Nakajima T
J Cardiovasc Pharmacol; 2006 Feb; 47(2):314-21. PubMed ID: 16495772
[TBL] [Abstract][Full Text] [Related]
19. Effect of azelnidipine and amlodipine on single cell mechanics in mouse cardiomyocytes.
Iribe G; Kaihara K; Ito H; Naruse K
Eur J Pharmacol; 2013 Sep; 715(1-3):142-6. PubMed ID: 23747592
[TBL] [Abstract][Full Text] [Related]
20. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]